274 related articles for article (PubMed ID: 11848456)
21. Use of implantable venous access devices in children with severe hemophilia: benefits and burden.
Van Dijk K; Van Der Bom JG; Bax KN; Van Der Zee DC; Van Den Berg MH
Haematologica; 2004 Feb; 89(2):189-94. PubMed ID: 15003894
[TBL] [Abstract][Full Text] [Related]
22. [Prospective matched control study concerning the treatment and quality of life of hemophiliacs with inhibitors].
Honda K; Nagao T; Kamiya T; Yoshioka A; Miyazaki T; Takeda T; Mori K; Fukutake K; Hanabusa H; Taki M; Mohri H; Miyama J; Takamatsu J; Kinoshita S; Shirahata A
Rinsho Ketsueki; 1998 Jun; 39(6):416-21. PubMed ID: 9695668
[TBL] [Abstract][Full Text] [Related]
23. Management of factor VIII inhibitors: evolution and current status.
Bloom AL
Haemostasis; 1992; 22(5):268-75. PubMed ID: 1478538
[TBL] [Abstract][Full Text] [Related]
24. Factor VIII inhibitor treatment. Immune tolerance.
Nilsson IM
Semin Hematol; 1994 Apr; 31(2 Suppl 4):44-8. PubMed ID: 7939775
[No Abstract] [Full Text] [Related]
25. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome.
Oldenburg J; Schwaab R; Brackmann HH
Vox Sang; 1999; 77 Suppl 1():49-54. PubMed ID: 10529689
[TBL] [Abstract][Full Text] [Related]
26. Immune tolerance therapy dose as an outcome predictor.
DiMichele D
Haemophilia; 2003 Jul; 9(4):382-6. PubMed ID: 12828672
[TBL] [Abstract][Full Text] [Related]
27. New data from the Italian National Register of Congenital Coagulopathies, 2016 Annual Survey.
Abbonizio F; Hassan HJ; Riccioni R; Santagostino E; Arcieri R; Giampaolo A;
Blood Transfus; 2020 Jan; 18(1):58-66. PubMed ID: 30865582
[TBL] [Abstract][Full Text] [Related]
28. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I
Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207
[TBL] [Abstract][Full Text] [Related]
29. Inhibitors in congenital haemophilia.
Brettler DB
Baillieres Clin Haematol; 1996 Jun; 9(2):319-29. PubMed ID: 8800508
[TBL] [Abstract][Full Text] [Related]
30. Immune tolerance induction and the treatment of hemophilia. Malmö protocol update.
Berntorp E; Astermark J; Carlborg E
Haematologica; 2000 Oct; 85(10 Suppl):48-50; discussion 50-1. PubMed ID: 11187871
[TBL] [Abstract][Full Text] [Related]
31. [Improvement in anti-hemophilic preparations and its problems. 3. Treatment of hemophilia patients with inhibitors; induction of immune tolerance by a low or intermediate dose regimen].
Iizuka A
Rinsho Ketsueki; 1988 May; 29(5):640-8. PubMed ID: 3145995
[No Abstract] [Full Text] [Related]
32. Canadian multi-institutional survey of immune tolerance therapy (ITT) -- experience with the use of recombinant factor VIII for ITT.
Barnes C; Rivard GE; Poon MC; Teitel J; Pai M; Kern M; Blanchette VS; Carcao M;
Haemophilia; 2006 Jan; 12(1):1-6. PubMed ID: 16409169
[TBL] [Abstract][Full Text] [Related]
33. [Risk of the appearance of inhibitors linked to the administration of factors VIII and IX. Review of the literature].
Calvez T; Costagliola D
Transfus Clin Biol; 1994; 1(6):427-35. PubMed ID: 7881588
[TBL] [Abstract][Full Text] [Related]
34. How will immune tolerance protocols affect self-sufficiency goals?
Brackmann HH
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S77-9. PubMed ID: 7795144
[TBL] [Abstract][Full Text] [Related]
35. Inhibitors in haemophilia: a primer.
DiMichele DM
Haemophilia; 2000 Jul; 6 Suppl 1():38-40. PubMed ID: 10982266
[No Abstract] [Full Text] [Related]
36. Factor VIII inhibitors. Immune tolerance induction: is it cost effective? We know too little.
Aledort LM
Semin Thromb Hemost; 2000; 26(2):189-93. PubMed ID: 10919412
[TBL] [Abstract][Full Text] [Related]
37. Successful induction of immune tolerance with FIX recombinant in a patient with haemophilia B with inhibitor.
Soto I; Vicente JM; Corte JR; Urgellés MF; Pinto CR
Haemophilia; 2004 Jul; 10(4):401-4. PubMed ID: 15230957
[TBL] [Abstract][Full Text] [Related]
38. Rituximab in the treatment of high responding inhibitors in severe haemophilia A.
Moschovi M; Aronis S; Trimis G; Platokouki H; Salavoura K; Tzortzatou-Stathopoulou F
Haemophilia; 2006 Jan; 12(1):95-9. PubMed ID: 16409183
[TBL] [Abstract][Full Text] [Related]
39. [The young hemophiliac, inhibitors and immune tolerance].
Rothschild C
Transfus Clin Biol; 1999 Jun; 6(3):191-4. PubMed ID: 10422212
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in the management of haemophilia and christmas disease.
Biggs R
Clin Haematol; 1979 Feb; 8(1):95-114. PubMed ID: 367667
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
